Dive Brief:
- Clairity has raised $43 million to commercialize a platform that predicts a woman’s five-year risk of breast cancer, the company said Thursday.
- The Clairity Breast platform uses artificial intelligence to analyze 2D mammogram images. Clairity won de novo authorization for the product in June.
- Using the new Series B funding, Clairity plans to accelerate U.S. commercialization and expand partnerships with leading imaging centers and health systems.
Dive Insight:
Clairity trained its AI model on mammogram images matched with five-year outcome data. The process was designed to enable the model to identify patterns in breast tissue that correlate with future cancer development.
The FDA de novo authorization supported the use of the model to predict future breast cancer risk. With the regulatory barrier to market cleared, ACE Global Equity and Santé Ventures have led a financing round to support commercialization. Clairity said it has initially targeted “marquee health systems” and is now ready to expand the rollout.
Commercial partnerships are underway, Clairity CEO Jeff Luber said in a statement. The funding will support reimbursement initiatives and partnerships to make Clairity Breast accessible across community imaging centers nationwide.
The funding will also support Clairity’s R&D plans. The company’s pipeline includes Clairity Breast 3D and Clairity Heart, which is designed to predict cardiovascular risk from a routine imaging exam. The move into cardiovascular disease is part of a push to use the deep learning framework that underpins Clairity Breast to develop AI-based predictive offerings in other therapeutic areas.
